Table 2. Demographic and Clinical Characteristics Associated With CIN2+ Recurrence at 6 Months.
| Age-Adjusted Models | Multivariate Model: HAART and Predictors (N = 206) | |||
|---|---|---|---|---|
|
|
|
|||
| HR (95% CI) | P | AHR (95% CI) | P | |
| Time-independent variables (baseline) | ||||
| Demographics | ||||
| Age | 1.70 (0.70 to 4.15) | 0.24 | 1.79 (0.78 to 4.11) | 0.17 |
| Site* | ||||
| Lumumba | 1.00 (Ref) | 1.00 (Ref) | ||
| Kisumu district hospital | 2.31 (0.93 to 5.75) | 0.073 | 2.26 (0.72 to 7.11) | 0.16 |
| Study referral | 1.54 (0.19 to 12.22) | 0.681 | 4.25 (0.38 to 47.52) | 0.24 |
| Has current partner | 1.20 (0.39 to 3.69) | 0.75 | ||
| Reproductive characteristics | ||||
| Combined oral contraceptive | 0 (n/a) | n/a | ||
| Injectable (Depo Provera) | 1.06 (0.38 to 2.93) | 0.91 | ||
| Implant (Jadelle) | 0 (n/a) | n/a | ||
| Intrauterine device in place | 0 (n/a) | n/a | ||
| No. past pregnancies | 0.60 (0.39 to 0.91) | 0.02 | 0.66 (0.43 to 1.00) | 0.05 |
| LEEP characteristics | ||||
| Pathology on LEEP specimen | ||||
| Less than CIN2+ | 1.00 (Ref) | |||
| CIN2+ | 2.21 (0.29 to 16.86) | 0.45 | ||
| Microinvasive cancer | 4.00 (0.36 to 44.31) | 0.26 | ||
| Lesion size >2.5 cm | 2.04 (0.74 to 5.64) | 0.17 | ||
| HIV-related characteristics | ||||
| Time since HIV diagnosis (mo) | 1.00 (0.97 to 1.02) | 0.99 | ||
| Most advanced WHO stage | ||||
| Stage 1 | 1.00 (Ref) | |||
| Stage 2 | 2.73 (0.54 to 13.72) | 0.22 | ||
| Stage 3 | 1.91 (1.65 to 9.89) | 0.44 | ||
| Stage 4 | 7.96 (1.64 to 38.54) | 0.01 | ||
| Time-dependent HIV-related variables | ||||
| On HAART at follow-up visit | 2.66 (0.78 to 9.12) | 0.12 | 0.57 (0.10 to 3.31) | 0.53 |
| HAART regimen switch before recurrence | 1.22 (0.16 to 9.62) | 0.85 | ||
| CD4+ count at visit | ||||
| <200 | 4.81 (1.85 to 12.52) | <0.01 | ||
| 201–350 | 1.39 (0.37 to 5.19) | 0.63 | ||
| >350 | 1.00 (Ref) | |||
| CD4+ count nadir† | ||||
| <200 | 4.08 (1.31 to 12.68) | 0.01 | 8.32 (1.22 to 56.87) | 0.03 |
| 201–350 | 2.26 (0.56 to 9.14) | 0.25 | 3.19 (0.42 to 24.35) | 0.26 |
| >350 | 1.00 (Ref) | 1.00 (Ref) | ||
*
Participants were recruited from 3 sites within the FACES program: Lumumba health center HIV, Kisumu District Hospital, and from a couples HIV prevention study. Clinical and demographic characteristics did not differ among study sites (data not shown).
†
CD4+ nadir defined as lowest CD4+ recorded before recurrence visit and/or before initiation on HAART among HAART users.
AHR, adjusted hazard ratio; HR, hazard ratio.